Physician profile
Telciane Vesa
NPI 1295932168
$2,116.86
in general payments reported to CMS, 2019-2025
14 companies · $691 in 2025
The $691 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2021: $232 · 2022: $54.86 · 2023: $106 · 2024: $245 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $544 · Food and Beverage: $498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $543.84 |
| Food and Beverage | $498.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Enterra Medical, INC. | $921.14 | 2024-2025 | |
| Boston Scientific Corporation | $711.94 | 2019-2023 | Spyglass |
| Abbvie INC. | $68.69 | 2019-2021 | |
| W. L. Gore & Associates, INC. | $64.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.18 | 2019-2022 | |
| Celgene Corporation | $58.58 | 2021-2022 | |
| Gilead Sciences, INC. | $51.92 | 2019 | |
| Ethicon INC. | $48.95 | 2023 | Monarch Platform |
| Merck Sharp & Dohme LLC | $44.65 | 2021 | |
| Janssen Biotech, INC. | $25.22 | 2019 | |
| Novo Nordisk INC | $19.07 | 2021 | |
| Ambu INC. | $15.41 | 2024 | |
| Conmed Corporation | $14.58 | 2022 | |
| Olympus America INC. | $13.08 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Telciane Vesa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.